Cargando…
LINC01116 Promotes Doxorubicin Resistance in Osteosarcoma by Epigenetically Silencing miR-424-5p and Inducing Epithelial-Mesenchymal Transition
Background: Development of resistance to doxorubicin-based chemotherapy limits its curative effect in osteosarcoma. In the current study, we focused on investigating the mechanisms underlying the development of doxorubicin resistance in osteosarcoma. Methods: The human osteosarcoma cell line MG-63 a...
Autores principales: | Li, Ran, Ruan, Qing, Zheng, Jia, Zhang, Butian, Yang, Hongliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982720/ https://www.ncbi.nlm.nih.gov/pubmed/33762953 http://dx.doi.org/10.3389/fphar.2021.632206 |
Ejemplares similares
-
Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway
por: Shang, Bin, et al.
Publicado: (2021) -
Promising Advances in LINC01116 Related to Cancer
por: Xu, Yating, et al.
Publicado: (2021) -
Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
por: Dong, Bo, et al.
Publicado: (2020) -
LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
por: Wang, Junbin, et al.
Publicado: (2020) -
LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma [Retraction]
Publicado: (2023)